+183%

est. 2Y upside i

HealthcareSeries A

Using AI to help dementia patients age at home

Rank

#101

Sector

Healthtech

Est. Liquidity

~5Y

Data Quality

Data: Medium

Craniometrix offers significant equity upside potential given its high growth and strategic partnerships, but the lack of disclosed valuation and reliance on regulatory programs add risk.

Last updated: July 19, 2026

Bull (30%)+296%

If Craniometrix successfully IPO's or gets acquired at a premium multiple of 15x on $37.6M ARR, equity could return ~296% after 20% dilution.

Base (45%)+170%

Assuming convergence to 10x multiple on $37.6M ARR, equity returns ~170% net of dilution.

Bear (25%)+70%

Multiple compresses to 6x due to competition or slowed growth, yielding ~70% upside, still above preference stack.

Est. time to liquidity~5.0 years

Preference Stack Risk

moderate

Funding Intensity

269%

Total funding of $21.5M represents 18% of estimated $120M valuation, moderate risk.

Dilution Risk

high

Additional funding rounds expected within 24 months, diluting common shareholders by ~20%.

Secondary Liquidity

none

No secondary market activity reported.

View all 9 open roles at Craniometrix →

Last updated: May 18, 2026

Questions to Ask at the Interview

Strategic questions based on Craniometrix's data — designed to show you've done your homework.

  • 1

    “How does Craniometrix plan to expand beyond the GUIDE program?”

  • 2

    “What is the customer acquisition cost and unit economics?”

  • 3

    “How does the equity package compare to later-stage startups?”

Community

Valuation Sentiment

Our model estimates +183% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.